Bioulac-Sage Paulette, Sempoux Christine, Balabaud Charles
Inserm U 1053, Université Bordeaux, 146 rue Léo Saignat, 33076 Bordeaux, France.
Service of Clinical Pathology, Lausanne University Hospital, Institute of Pathology, Rue du Bugnon 25, CH-1011 Lausanne, Switzerland.
Gastroenterol Clin North Am. 2017 Jun;46(2):253-272. doi: 10.1016/j.gtc.2017.01.003.
Hepatocellular adenomas (HCAs) are rare benign tumors. This single entity has been split into 3 subtypes corresponding to specific mutations: HNF1α-inactivated HCA; inflammatory HCA related to different mutations, all leading to activation of STAT3 pathway; and β-catenin-activated HCA related to CTNNB1 mutations. The risk of malignant transformation depends on the level of β-catenin activation, reported mainly for exon 3, including S45. It is possible using specific immunohistochemical markers to identify the 3 different HCA subtypes and the level of β-catenin activation. Fewer than 10% of HCAs remain unclassified.
肝细胞腺瘤（HCA）是罕见的良性肿瘤。这一单一实体已被分为3种亚型，分别对应特定的突变：HNF1α失活型HCA；与不同突变相关的炎症性HCA，所有这些突变均导致STAT3通路激活；以及与CTNNB1突变相关的β-连环蛋白激活型HCA。恶性转化风险取决于β-连环蛋白的激活水平，主要针对外显子3（包括S45）进行报道。利用特定的免疫组化标志物能够识别这3种不同的HCA亚型以及β-连环蛋白的激活水平。不到10%的HCA仍未分类。
